Stay informed with free updates
Simply sign up to the Pharmaceuticals sector myFT Digest — delivered directly to your inbox.
GSK is selling its remaining stake in Haleon, the consumer healthcare company it spun off and listed in London in July 2022, in a move that underscores how pharmaceutical groups are streamlining their businesses to focus on high-value medicines.
The sale of the 4.2 per cent stake will help the FTSE 100 drugmaker to raise just over £1bn, based on the current Haleon valuation. The move marks the end of GSK’s links to the maker of Panadol painkillers and Sensodyne toothpaste.
The British pharmaceutical company’s exit from Haleon was anticipated and it had made three previous stock disposals since May 2023, when it held 12.9 per cent of the company’s shares.
In total, stock disposals over the past year are expected to help GSK raise just under £4bn, which can be redirected to reducing debt or for mergers and acquisitions.
The listing and stock sale have come as pharmaceutical businesses seek to focus on developing new medicines that can be sold at high prices and cutting back on lower-earning divisions such as consumer healthcare.
Haleon was formed in 2019 as a joint venture of Pfizer and GSK’s consumer health assets. The decision to list the division in 2022 marked the largest public offering in London in a decade.
It came after years of pressure from shareholders, with activist investor Elliott Advisors building a stake in the UK drugmaker and pushing GSK to speed up the process.
Haleon has undertaken its own restructuring programme, taking steps to dispose of non-core brands, such as its sale of lip balm brand ChapStick to private equity group Yellow Wood Partners for $430mn.
GSK is not the only pharmaceutical company to take steps to streamline its business. France’s Sanofi is also preparing for a potential separation of its consumer healthcare division, while Johnson & Johnson spun out its consumer arm Kenvue in 2023.
Pfizer retained a 32 per cent stake in Haleon after its IPO and it continues to hold an 18.3 per cent position. The US drugmaker has also reduced its stake in recent months and plans to eventually exit the company.
Announcing the sale after market close on Thursday, GSK said the offer price would be determined through an accelerated bookbuild offering process that is to start immediately.
Read the full article here
